AbbVie’s HCV treatment receives first for shorter treatment cycle 30-Sep-2019 By Ben Hargreaves US FDA granted expanded approval for Mavyret that will allow patients to be treated for the hepatitis C virus in eight weeks.
AbbVie allows generic manufacture of HCV treatment in 99 countries 19-Nov-2018 By Ben Hargreaves A licensing agreement with MPP will allow access to Mavyret in a number of low- and middle-income countries and territories at ‘affordable prices’.